Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | June 04, 2024 | June 06, 2024 |
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | January 12, 2026 | March 03, 2026 |
| ZyVersa Therapeutics, Inc.ZVSA · Entity 8639 | Director | July 11, 2025 | July 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date June 04, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 283,498 |
Reported balance
After 2024-06-04 transaction · row 1
1 source rowRow 1 · 2024-06-04 · Exercise / conversion · Acquired 11,904 · Balance 283,498 F1: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Exercise / conversion · Disposed 11,904 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective June 4, 2024, the Board of Directors accelerated the vesting of outstanding and unvested equity totaling 11, 904 shares of common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 54,876 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 54,876 · Balance 54,876 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
ZyVersa Therapeutics, Inc.
Report date July 11, 2025 · Filed July 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2035-07-11 | Direct | 11,066 |
Reported balance
After 2025-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-11 · Grant · Acquired 11,066 · Balance 11,066 F1: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2021 Filed May 28, 2021 20:05 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 22,954 | $3.67 | $84,241.18 |
DisclosureSEC source: 0000805928-21-000099 · wf-form4_162223233198745.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:08 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 24,000 | $22.06 | $529,440.00 |
DisclosureSEC source: 0000805928-21-000046 · wf-form4_161463290842472.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,352 F1 · kind: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2020. F1 · price: Effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.56 to $22.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:16 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 545 | $18.70 | $10,191.50 |
DisclosureSEC source: 0000805928-21-000024 · wf-form4_161368656384787.xml · nonDerivative · entry 4 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,352 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 22:16 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,032 | $18.70 | $19,298.40 |
DisclosureSEC source: 0000805928-21-000024 · wf-form4_161368656384787.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,113 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,784 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000024 · wf-form4_161368656384787.xml · nonDerivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,897 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,377 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000024 · wf-form4_161368656384787.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,145 F1 · shares: This reflects the number of shares that became vested as of February 16, 2021 upon the attainment of certain performance criteria. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 17:53 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 916 | $17.81 | $16,313.96 |
DisclosureSEC source: 0001179110-20-012293 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,345 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 27, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2020 Filed Dec 30, 2020 17:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012293 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,261 F1 · shares: This reflects the number of restricted stock units that became vested as of December 27, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 27, 2020. F3 · balance_after: Includes 1885 shares acquired under the Axogen, Inc. employee stock purchase plan on June 30, 2020. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 20:15 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 379 | $16.42 | $6,223.18 |
DisclosureSEC source: 0001179110-20-012171 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,076 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units granted on December 18, 2020. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 20:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-012171 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,455 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2020. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:57 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock · Derivative | 4,046 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001179110-20-009860 · edgar.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,954 Underlying: Common Stock · 4,046 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:57 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock · Derivative | 9,000 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001179110-20-009860 · edgar.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 9,000 shares Expires 2021-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:57 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 13,046 | $3.67 | $47,878.82 |
DisclosureSEC source: 0001179110-20-009860 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the cash exercise of stock options for a total of 13,046 shares. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 18:43 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-20-014773 · form4.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 23, 2023. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 11:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001179110-20-006736 · edgar.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2020-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 11:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 125,000 | $3.50 | $437,500.00 |
DisclosureSEC source: 0001179110-20-006736 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: 1. This Form is being filed to report the cash exercise of a stock option for a total of 125,000 shares. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003912 · edgar.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:15 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 24,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001179110-20-003912 · edgar.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 529 | $14.68 | $7,765.72 |
DisclosureSEC source: 0001179110-20-001944 · edgar.xml · nonDerivative · entry 4 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,484 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001944 · edgar.xml · nonDerivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,013 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,002 | $14.68 | $14,709.36 |
DisclosureSEC source: 0001179110-20-001944 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,230 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001944 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,232 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:31 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantCommon Stock | 38,400 | $1.30 | $49,920.00 |
DisclosureSEC source: 0001140361-20-003647 · form4.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,271 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on February 14, 2020. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 567 | $16.73 | $9,485.91 |
DisclosureSEC source: 0001179110-19-013082 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,543 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013082 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,110 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 16:35 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0001127602-19-023223 · form4.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-28 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 3,377 | $17.57 | $59,333.89 |
DisclosureSEC source: 0001179110-19-002058 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,260 Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:37 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014322 · edgar.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:37 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 18,500 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001179110-18-014322 · edgar.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2028-12-27 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| November 30, 2018 Filed Dec 5, 2018 00:30 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 45,000 | $33.00 | $1,485,000.00 |
DisclosureSEC source: 0001179110-18-013429 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,865 F1 · price: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan (the "Plan") adopted by the reporting person on September 7, 2018, as amended November 9, 2018. The sales resulted in the completion of the Plan so no more shares will be sold pursuant to the Plan. F2 · price: The price reported is the actual sale price for all of these shares that were sold in multiple transactions. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the sale of the shares. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 22:16 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 20,000 | $32.25 | $645,000.00 |
DisclosureSEC source: 0001179110-18-012899 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,865 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.51. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 12:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-18-004789 · edgar.xml · derivative · entry 6 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 12:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 16,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001179110-18-004789 · edgar.xml · derivative · entry 5 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2021-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 12:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,874 | $38.50 | $72,149.00 |
DisclosureSEC source: 0001179110-18-004789 · edgar.xml · nonDerivative · entry 4 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,865 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 31,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 28,104 shares of common stock. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 12:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,000 | $4.81 | $72,150.00 |
DisclosureSEC source: 0001179110-18-004789 · edgar.xml · nonDerivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 31,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 28,104 shares of common stock. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 12:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,022 | $38.50 | $39,347.00 |
DisclosureSEC source: 0001179110-18-004789 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,739 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 31,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 28,104 shares of common stock. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 12:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 16,000 | $2.46 | $39,360.00 |
DisclosureSEC source: 0001179110-18-004789 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 31,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 28,104 shares of common stock. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:27 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 36,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-18-003516 · edgar.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2018-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:27 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,905 | $33.95 | $98,624.75 |
DisclosureSEC source: 0001179110-18-003516 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,761 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 36,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 33,095 shares of common stock. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 22:27 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 36,000 | $2.74 | $98,640.00 |
DisclosureSEC source: 0001179110-18-003516 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 36,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 33,095 shares of common stock. Read SEC document |
| December 30, 2017 Filed Mar 14, 2017 23:31 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 23,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-004608 · edgar.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 92,000 shares Expires 2018-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:55 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015746 · edgar.xml · derivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 Underlying: Common Stock · 3,700 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:55 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 22,100 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015746 · edgar.xml · derivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 10,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-012731 · edgar.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 10,000 shares Expires 2018-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,450 | $18.90 | $27,405.00 |
DisclosureSEC source: 0001179110-17-012731 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,666 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 10,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 8,550 shares of common stock. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 10,000 | $2.74 | $27,400.00 |
DisclosureSEC source: 0001179110-17-012731 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 10,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 8,550 shares of common stock. Read SEC document |
| August 27, 2017 Filed Aug 29, 2017 20:58 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 23,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-011880 · edgar.xml · derivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 23,000 shares Expires 2018-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2017 Filed Aug 29, 2017 20:58 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 3,785 | $16.65 | $63,020.25 |
DisclosureSEC source: 0001179110-17-011880 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,116 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 23,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 19,215 shares of common stock. Read SEC document |
| August 27, 2017 Filed Aug 29, 2017 20:58 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 23,000 | $2.74 | $63,020.00 |
DisclosureSEC source: 0001179110-17-011880 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 23,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 19,215 shares of common stock. Read SEC document |
| December 30, 2016 Filed Mar 14, 2017 23:31 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 23,000 | $2.74 | $63,020.00 |
DisclosureSEC source: 0001179110-17-004608 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel & SVP BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.